Invention Publication
- Patent Title: SARS-COV2 MAIN PROTEASE INHIBITORS
-
Application No.: US18365919Application Date: 2023-08-04
-
Publication No.: US20240239807A1Publication Date: 2024-07-18
- Inventor: Stephen E. Ammann , Xinpei Cai , Eda Y. Canales , Weng K. Chang , Gregory F. Chin , Henok H. Kinfe , Scott E. Lazerwith , Jessica L. McKinley , Michael R. Mish , Devan Naduthambi , Jason K. Perry , Kevin X. Rodriguez , Scott D. Schroeder , Christopher J. Swank , Joshua J. Van Veldhuizen
- Applicant: Gilead Sciences, Inc.
- Applicant Address: US CA Foster City
- Assignee: Gilead Sciences, Inc.
- Current Assignee: Gilead Sciences, Inc.
- Current Assignee Address: US CA Foster City
- Main IPC: C07D495/04
- IPC: C07D495/04 ; A61P31/14 ; C07D401/04 ; C07D401/14 ; C07D405/14 ; C07D409/14 ; C07D413/14 ; C07D417/14 ; C07D471/04 ; C07D487/04 ; C07D487/10 ; C07D491/107 ; C07D491/113 ; C07D498/04 ; C07D513/04 ; C07D519/00
Abstract:
The present disclosure relates to compounds of Formula I:
and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Information query
